Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.
about
Successful immunotherapy with matrix metalloproteinase-derived peptides in adjuvant arthritis depends on the timing of peptide administrationAnimal models of myasthenia gravis: utility and limitationsSpecific immunotherapy of experimental myasthenia gravis by a novel mechanism.Acetylcholine receptors and myasthenia.Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis.Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment.Nasal tolerance induction as a potential means of immunotherapy for autoimmune diseases: implications for clinical medicine.Vaccines against myasthenia gravis.Pemphigus in the XXI century: new life to an old story.Development of novel therapies for MG: Studies in animal models.Current and emerging treatments for the management of myasthenia gravis.Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?Pathogenic immune mechanisms at the neuromuscular synapse: the role of specific antibody-binding epitopes in myasthenia gravis.A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis.When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies.
P2860
Q24800796-42C5BC06-D31D-4304-B070-DE6EEA5840DBQ26750632-0F6A3BF8-D142-4473-9517-3CF8123CD535Q33831279-449196AE-A2DD-469A-BC09-79460C1A35F8Q33862589-B5D824E0-C87C-4928-A7E3-AD4AEC19F3E4Q33901936-CBA47B95-80A5-4596-9A2F-944B95AB0F3EQ33903455-07D713FA-2617-49C1-920F-E8C10C97A92CQ34106906-1857CB0C-1F2B-46E8-8497-2A3D36D1BF0CQ34433908-E0304F26-642A-4A19-A1DD-717E232915F8Q36668531-4476A04C-780E-4AFD-941A-DD4B99175371Q37713733-05E251B7-D8EC-4C9A-8B3D-0D8B60E7D357Q37918361-D7545E15-C0E3-492C-9FC1-03737FEB2888Q37967185-6ED59E26-D44C-4C2A-B72F-96DE8FB44F2FQ38161532-FDBAEA90-ACEA-4D91-B8CB-23507233DBC8Q41673068-F57EE004-9934-4D8A-9C12-32802D1FE446Q42733420-C646443E-520C-4606-854B-DAF0C00BFFE3Q49280339-036A69D5-D341-4EFF-8CA4-644DDC800093
P2860
Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@ast
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@en
type
label
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@ast
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@en
prefLabel
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@ast
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@en
P2093
P2860
P356
P1476
Antigen-specific modulation of ...... holine receptor alpha-subunit.
@en
P2093
P2860
P304
P356
10.1073/PNAS.96.14.8086
P407
P577
1999-07-01T00:00:00Z